02 February 2026
02 February 2026
Historically a steel production hub, Lehigh Valley will now help manufacture Lilly’s weight loss drug hopeful retatrutide.
The company’s sales grew 9.9% YoY – driven by a diverse range of portfolio classics and new launches.
The PreCheck programme, first unveiled in June 2025, aims to speed up drug facility construction.
Kyowa Kirin will file for rocatinlimab’s US approval, which was once Amgen’s most late-stage pipeline candidate.
The programme will focus on accelerating treatments for rare diseases, most of which currently lack approved therapies.
The CHMP decision is based on Phase III AMPLITUDE study results in 696 mHSPC patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
